600566 济川药业
已收盘 02-05 15:00:00
资讯
新帖
简况
瞄准过敏性鼻炎新药!济川药业“牵手”普祺医药,后者正冲刺港股IPO
市场资讯 · 02-03 22:09
瞄准过敏性鼻炎新药!济川药业“牵手”普祺医药,后者正冲刺港股IPO
康方生物(09926)授予济川药业伊喜宁®的独家商业化权益
智通财经 · 02-03 19:13
康方生物(09926)授予济川药业伊喜宁®的独家商业化权益
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,2月2日股价下跌1.8%
证券之星 · 02-02 22:23
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,2月2日股价下跌1.8%
济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议
智通财经 · 02-02 18:17
济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议
济川药业(600566)披露全资子公司使用闲置募集资金购买结构性存款进展,1月22日股价下跌0.64%
证券之星 · 01-22
济川药业(600566)披露全资子公司使用闲置募集资金购买结构性存款进展,1月22日股价下跌0.64%
济川药业(600566)披露全资子公司利用闲置募集资金进行现金管理的进展公告,1月19日股价上涨0.72%
证券之星 · 01-19
济川药业(600566)披露全资子公司利用闲置募集资金进行现金管理的进展公告,1月19日股价上涨0.72%
每周股票复盘:济川药业(600566)首次回购股份10万股支付约262万元
证券之星 · 01-18
每周股票复盘:济川药业(600566)首次回购股份10万股支付约262万元
每周股票复盘:济川药业(600566)回购尚未实施,行权致股本变动
证券之星 · 01-11
每周股票复盘:济川药业(600566)回购尚未实施,行权致股本变动
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,1月5日股价上涨0.61%
证券之星 · 01-05
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,1月5日股价上涨0.61%
流感疫情持续,防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续,防控系统工程再受考验
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%
证券之星 · 2025-12-01
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%
流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?
第一财经 · 2025-11-26
流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?
济川药业最新公告:拟2500万元-5000万元回购股份
证券之星 · 2025-11-24
济川药业最新公告:拟2500万元-5000万元回购股份
每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票
证券之星 · 2025-11-23
每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票
济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%
证券之星 · 2025-11-21
济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%
济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%
证券之星 · 2025-11-18
济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%
济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%
证券之星 · 2025-10-31
济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%
济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%
证券之星 · 2025-10-28
济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%
图解济川药业三季报:第三季度单季净利润同比下降47.19%
证券之星 · 2025-10-27
图解济川药业三季报:第三季度单季净利润同比下降47.19%
每周股票复盘:济川药业(600566)限制行权期为10月23日至27日
证券之星 · 2025-10-19
每周股票复盘:济川药业(600566)限制行权期为10月23日至27日
加载更多
公司概况
公司名称:
湖北济川药业股份有限公司
所属行业:
医药制造业
上市日期:
2001-08-22
主营业务:
湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒及其糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片,健胃消食口服液、硫酸镁钠钾口服用浓溶液及甘海胃康胶囊,妇炎舒胶囊、蛋白琥珀酸铁口服溶液。济川有限荣登“2024中国雇主品牌影响力100强”,荣获“江苏省守合同重信用企业”称号,获评“高质量发展综合奖”“泰兴市2023年度科技创新十佳企业”等四大荣誉,济川有限及董事长曹龙祥荣获“国家科学技术进步二等奖”。
发行价格:
7.80
{"stockData":{"symbol":"600566","market":"SH","secType":"STK","nameCN":"济川药业","latestPrice":27.14,"timestamp":1770274801000,"preClose":26.77,"halted":0,"volume":6483821,"delay":0,"changeRate":0.0138,"floatShares":918000000,"shares":921000000,"eps":1.7922,"marketStatus":"已收盘","change":0.37,"latestTime":"02-05 15:00:00","open":26.78,"high":27.26,"low":26.53,"amount":175000000,"amplitude":0.0273,"askPrice":27.14,"askSize":66,"bidPrice":27.13,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.7922,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":5,"adr":0,"adjPreClose":26.77,"symbolType":"stock","openAndCloseTimeList":[[1770255000000,1770262200000],[1770267600000,1770274800000]],"highLimit":29.45,"lowLimit":24.09,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921344260,"isCdr":false,"pbRate":1.81,"roa":"--","peRate":15.143399,"roe":"7.12%","epsLYR":2.76,"committee":0.656006,"marketValue":25005000000,"turnoverRate":0.0071,"status":0,"floatMarketCap":24921000000},"requestUrl":"/m/hq/s/600566","defaultTab":"news","newsList":[{"id":"2608389714","title":"瞄准过敏性鼻炎新药!济川药业“牵手”普祺医药,后者正冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389714","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608389714?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:09","pubTimestamp":1770127740,"startTime":"0","endTime":"0","summary":" 济川药业将布局瞄准过敏性鼻炎新药。 2月3日,济川药业发布公告称,公司全资子公司济川药业集团有限公司与北京普祺医药科技股份有限公司签署独家商业化合作协议,约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼鼻喷雾剂在中国的商业化。 值得一提的是,普美昔替尼的研发方普祺医药,目前正在冲刺港股IPO。这也意味着,此次商业授权将给普祺医药带来一笔不菲的收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-03/doc-inhkqfvf4193850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VT","BK0028","BK4588","BK1161","BK0012","BK0187","BK0239","159938","BK1574","BK1515","600566","BK0188","BK0201","BK4585","VXUS","BK0077","09939"],"gpt_icon":0},{"id":"2608820376","title":"康方生物(09926)授予济川药业伊喜宁®的独家商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2608820376","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608820376?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:13","pubTimestamp":1770117191,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康方生物 公布,公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公司与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医药有限公司于近日签署《独占性商业化权益协议》,康方生物授权济川药业在合作期限内,在中华人民共和国拥有公司自主开发并已获批上市的伊喜宁的独家商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348735423.USD","LU0348767384.USD","LU2488822045.USD","LU0348766576.USD","LU1794554557.SGD","LU0540923850.HKD","LU0417516902.SGD","LU1720050803.USD","BK1574","09926","LU2778985437.USD","LU0348827113.USD","BK0188","BK1161","LU0634319403.HKD","BK0187","LU0417516571.SGD","600566","BK0239","BK0028","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0561508036.HKD","LU2399975544.HKD","BK0077","IE00BPRC5H50.USD","LU1961090484.USD","LU2476274720.SGD","BK0012","BK0201","LU0348784397.USD","LU2476274308.USD","LU0417516738.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2608867960","title":"济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,2月2日股价下跌1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608867960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608867960?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:23","pubTimestamp":1770042197,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,济川药业报收于25.59元,较前一交易日下跌1.8%,最新总市值为235.77亿元。近日,湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。公告显示,公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额为2,500万元至5,000万元,用于员工持股计划或股权激励,回购价格不超过38元/股,实施期限为董事会审议通过后12个月内。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566","BK0187","BK0188","BK0239","BK0028","BK0077","BK0012","BK0201"],"gpt_icon":0},{"id":"2608676850","title":"济川药业(600566.SZ)子公司与普祺医药签署独家商业化合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608676850","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608676850?lang=zh_cn&edition=full","pubTime":"2026-02-02 18:17","pubTimestamp":1770027475,"startTime":"0","endTime":"0","summary":"智通财经APP讯,济川药业(600566.SZ)公告,公司全资子公司济川药业集团有限公司(“济川有限”)与北京普祺医药科技股份有限公司(“普祺医药”)签署独家商业化合作协议,约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼(PG-011)鼻喷雾剂在中国的商业化。济川有限向普祺医药支付最高不超过1亿元(含税)的独家商业化权益的对价。公告显示,普美昔替尼(PG-011)是一款自主研发、具有完全知识产权的JAK1/2抑制剂,用于治疗过敏性鼻炎。交易完成后,公司将进一步加强产品线的丰富程度,有利于公司业务的可持续发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","BK0077","BK0187","BK1574","BK0188","BK0201","BK0239","BK0012","600566","09939","BK1515","BK0028"],"gpt_icon":0},{"id":"2605574464","title":"济川药业(600566)披露全资子公司使用闲置募集资金购买结构性存款进展,1月22日股价下跌0.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605574464","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605574464?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:40","pubTimestamp":1769074841,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘,济川药业报收于26.59元,较前一交易日下跌0.64%,最新总市值为244.99亿元。该股当日开盘26.7元,最高26.88元,最低26.44元,成交额达7383.96万元,换手率为0.3%。公司近日发布公告称,其全资子公司济川药业集团有限公司使用闲置募集资金7,000万元购买渤海银行泰州分行的结构性存款产品,产品名称为渤海银行WBS2600457结构性存款,期限为114天,投资期限自2026年1月21日至2026年5月15日,预计年化收益率区间为0.75%-2.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200029068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0201","BK0239","600566","BK0077","BK0028","BK0187"],"gpt_icon":0},{"id":"2604131407","title":"济川药业(600566)披露全资子公司利用闲置募集资金进行现金管理的进展公告,1月19日股价上涨0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604131407","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604131407?lang=zh_cn&edition=full","pubTime":"2026-01-19 22:48","pubTimestamp":1768834094,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘,济川药业报收于26.47元,较前一交易日上涨0.72%,最新总市值为243.88亿元。该股当日开盘26.28元,最高26.55元,最低26.05元,成交额达1.09亿元,换手率为0.45%。公司近日发布公告称,其全资子公司济川药业集团有限公司使用闲置募集资金7,000万元购买渤海银行泰州分行结构性存款,产品名称为渤海银行WBS2600391结构性存款,期限116天,预计年化收益率0.75%-2.30%。此前用于现金管理的7,000万元已按期赎回,取得收益52.64万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900036077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0201","BK0187","BK0077","600566","BK0239","BK0012"],"gpt_icon":0},{"id":"2604879925","title":"每周股票复盘:济川药业(600566)首次回购股份10万股支付约262万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604879925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604879925?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:35","pubTimestamp":1768678510,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,济川药业报收于26.28元,较上周的26.17元上涨0.42%。本周,济川药业1月16日盘中最高价报26.63元。济川药业当前最新总市值242.13亿元,在中药板块市值排名10/67,在两市A股市值排名880/5183。公司公告汇总湖北济川药业股份有限公司于2026年1月13日首次通过集中竞价交易方式回购公司股份,回购股份数量为100,000股,占公司总股本的0.01%,回购价格区间为26.13元/股至26.28元/股,已支付总金额2,619,944元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","BK0187","BK0239","BK0188","BK0028","600566","BK0201"],"gpt_icon":0},{"id":"2602536403","title":"每周股票复盘:济川药业(600566)回购尚未实施,行权致股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536403","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536403?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:11","pubTimestamp":1768075867,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,济川药业报收于26.17元,较上周的26.3元下跌0.49%。公司公告汇总湖北济川药业股份有限公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购股份的方案,拟用于员工持股计划或股权激励。湖北济川药业股份有限公司2022年限制性股票与股票期权激励计划首次授予股票期权第一个行权期在2025年第四季度累计行权855,400股,占当期可行权总量的49.88%。本次行权完成后,公司总股本由920,660,660股增至921,344,260股,实际控制人未发生变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566","BK0077","BK0187","BK0028","BK0012","BK0239","BK0201","BK0188"],"gpt_icon":0},{"id":"2601000896","title":"济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,1月5日股价上涨0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000896","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000896?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:11","pubTimestamp":1767607883,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,济川药业报收于26.46元,较前一交易日上涨0.61%,最新总市值为243.75亿元。该股当日开盘26.31元,最高26.71元,最低26.22元,成交额达1.33亿元,换手率为0.55%。公司近日发布公告称,湖北济川药业股份有限公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购股份的方案,拟用于员工持股计划或股权激励。公司将根据相关规定推进回购工作,并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600566","BK0201","BK0239","BK0187","BK0077","BK0028","BK0188"],"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续,防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末,全国流感疫情持续处于高流行水平。产业链协同响应,构建多层次供应保障流感防控是一项系统工程,需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中,上市药企正通过全产业链布局,搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示,金振口服液四季度市场需求回暖,正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批,其在儿科领域的应用场景进一步拓宽。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","600557","BK0012","BK0096","BK0187","BK0239","BK0164","BK0197","BK0186","002728","002393","BK0060","BK0097","BK0284","600079","BK0146","600566","BK0074","BK0196","000756","688276","BK0042","300244","BK0077","002603","BK0183","BK0086","301207","SG9999001069.SGD","BK0188","BK0201","BK0114","BK0250","BK0070","002317","300937","BK0046","BK0236","BK0175","603858","603882","000623","000999","BK0010"],"gpt_icon":0},{"id":"2588775364","title":"济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,12月1日股价上涨3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775364","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588775364?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:22","pubTimestamp":1764598977,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,济川药业报收于27.06元,较前一交易日上涨3.05%,最新总市值为249.28亿元。该股当日开盘26.86元,最高27.39元,最低26.5元,成交额达4.89亿元,换手率为1.97%。公司近日发布公告称,湖北济川药业股份有限公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,拟用于员工持股计划或股权激励。公司将根据相关规定推进回购工作,并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0201","BK0028","600566","BK0012","BK0187","BK0077","BK0239"],"gpt_icon":0},{"id":"2586238694","title":"流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586238694","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586238694?lang=zh_cn&edition=full","pubTime":"2025-11-26 13:35","pubTimestamp":1764135347,"startTime":"0","endTime":"0","summary":"【流感高峰期或在下个月!三款流感新药上市 速福达和奥司他韦还缺货吗?】“我们正全力保障速福达及原研奥司他韦(达菲)在医院端的充足、稳定供应。目前,这两款药物均已在全国实现了广泛的医院准入。今年速福达整体供应量是去年的3倍以上,我们正基于全国各地的实际需求,进行灵活、动态的持续供应调配。同时,如果个别地区突然出现流感疫情大幅上升,罗氏与经销商的保供团队也已经做好了充分的应急预案,将以最快速度响应,确保药品及时送达医疗机构。”罗氏制药这样表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263575284928.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575284928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002317","BK0028","BK0012","BK0187","BK0239","BK1191","600566","BK0188","BK0201","BK0077","06887"],"gpt_icon":0},{"id":"2585891463","title":"济川药业最新公告:拟2500万元-5000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2585891463","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585891463?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:02","pubTimestamp":1763978539,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称,公司计划使用自有资金以集中竞价交易方式回购部分公司股份,资金总额不低于2500万元(含)且不超过5000万元(含),回购价格不超过38元/股。回购期限为自董事会审议通过之日起12个月内。本次回购的股份将用于实施员工持股计划或股权激励。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0187","BK0201","BK0028","600566","BK0239","BK0012"],"gpt_icon":0},{"id":"2585103630","title":"每周股票复盘:济川药业(600566)拟注销17.18万股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103630?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:28","pubTimestamp":1763836094,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,济川药业报收于26.0元,较上周的27.75元下跌6.31%。本周,济川药业11月18日盘中最高价报28.14元。本周关注点公司公告汇总:济川药业拟回购注销171,800股限制性股票,涉及3名离职及5名考核不达标激励对象。湖北济川药业股份有限公司因3名激励对象离职、5名激励对象2022年度个人绩效考核不达标,根据激励计划相关规定,拟回购注销其已获授但尚未解除限售的首次授予限制性股票合计171,800股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0012","BK0188","BK0187","BK0077","600566","BK0201"],"gpt_icon":0},{"id":"2585340149","title":"济川药业(600566)披露2022年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告,11月21日股价下跌1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585340149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585340149?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:25","pubTimestamp":1763735143,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,济川药业报收于26.0元,较前一交易日下跌1.92%,最新总市值为239.56亿元。公司近日发布公告称,因3名激励对象离职、5名激励对象2022年度个人绩效考核不达标,根据2022年限制性股票与股票期权激励计划相关规定,拟回购注销其已获授但尚未解除限售的首次授予限制性股票合计171,800股。本次回购注销已于2025年9月9日经公司第十届董事会第十七次会议审议通过,并已完成信息披露及债权人公告程序,预计于2025年11月26日完成注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","600566","BK0028","BK0077","BK0188","BK0239","BK0187","BK0012"],"gpt_icon":0},{"id":"2584955337","title":"济川药业(600566)披露全资子公司使用闲置募集资金进行现金管理进展,11月18日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955337","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955337?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:19","pubTimestamp":1763475563,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘,济川药业报收于27.51元,较前一交易日下跌1.54%,最新总市值为253.27亿元。该股当日开盘27.82元,最高28.14元,最低27.41元,成交额达1.82亿元,换手率为0.72%。公司近日发布公告称,其全资子公司济川药业集团有限公司已开立募集资金现金管理专用结算账户,并使用闲置募集资金22,000万元进行现金管理。公司表示,相关事项已经履行董事会、股东大会审议程序,保荐机构亦发表同意意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566","BK0077","BK0012","BK0028","BK0201","BK0187","BK0239","BK0188"],"gpt_icon":0},{"id":"2579645790","title":"济川药业(600566)披露完成工商变更登记及换发营业执照,10月31日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579645790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579645790?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:16","pubTimestamp":1761905817,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,济川药业报收于25.06元,较前一交易日上涨1.21%,最新总市值为230.72亿元。公司近日发布公告称,湖北济川药业股份有限公司已于2025年8月22日和2025年9月19日分别召开第十届董事会第十六次会议及2025年第一次临时股东大会,审议通过《关于变更注册资本、取消监事会并修订<公司章程>的议案》。目前,公司已完成工商变更登记手续,并取得荆州市市场监督管理局换发的营业执照。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0077","BK0239","600566","BK0188","BK0201","BK0187"],"gpt_icon":0},{"id":"2578936344","title":"济川药业(600566)9月30日股东户数4.74万户,较上期增加7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578936344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578936344?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:17","pubTimestamp":1761643056,"startTime":"0","endTime":"0","summary":"证券之星消息,近日济川药业披露,截至2025年9月30日公司股东户数为4.74万户,较6月30日增加3405.0户,增幅为7.75%。在中药行业个股中,济川药业股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.36万户。从股价来看,2025年6月30日至2025年9月30日,济川药业区间跌幅为7.63%,在此期间股东户数增加3405.0户,增幅为7.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0077","BK0188","BK0187","600566","BK0239","BK0028","BK0012"],"gpt_icon":0},{"id":"2578142856","title":"图解济川药业三季报:第三季度单季净利润同比下降47.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578142856","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578142856?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:18","pubTimestamp":1761560325,"startTime":"0","endTime":"0","summary":"证券之星消息,济川药业2025年三季报显示,公司主营收入39.32亿元,同比下降32.27%;归母净利润10.22亿元,同比下降46.27%;扣非净利润8.59亿元,同比下降49.43%;其中2025年第三季度,公司单季度主营收入11.83亿元,同比下降33.17%;单季度归母净利润2.98亿元,同比下降47.19%;单季度扣非净利润2.39亿元,同比下降54.0%;负债率16.18%,投资收益1.57亿元,财务费用-5461.28万元,毛利率76.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700028237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566"],"gpt_icon":0},{"id":"2576041306","title":"每周股票复盘:济川药业(600566)限制行权期为10月23日至27日","url":"https://stock-news.laohu8.com/highlight/detail?id=2576041306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576041306?lang=zh_cn&edition=full","pubTime":"2025-10-19 04:12","pubTimestamp":1760818330,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,济川药业报收于25.26元,较上周的25.06元上涨0.8%。本周,济川药业10月17日盘中最高价报25.85元。济川药业当前最新总市值232.56亿元,在中药板块市值排名12/67,在两市A股市值排名789/5158。本周关注点公司公告汇总:济川药业首次授予股票期权第一个行权期实际可行权期间为2025年10月15日至2026年9月7日。公司公告汇总:济川药业限制行权期为2025年10月23日至2025年10月27日,期间全部激励对象将限制行权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","600566","BK0239","BK0012","BK0188","BK0201","BK0077","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770276524550,"stockEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":0.0117},{"period":"3month","weight":0.0585},{"period":"6month","weight":0.0117},{"period":"1year","weight":0.0459},{"period":"ytd","weight":0.0179}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北济川药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"47359人(较上一季度增加7.75%)","perCapita":"19388股","listingDate":"2001-08-22","address":"湖北省荆州市沙市区园林路时尚豪庭602室","registeredCapital":"92134万元","survey":" 湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒及其糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片,健胃消食口服液、硫酸镁钠钾口服用浓溶液及甘海胃康胶囊,妇炎舒胶囊、蛋白琥珀酸铁口服溶液。济川有限荣登“2024中国雇主品牌影响力100强”,荣获“江苏省守合同重信用企业”称号,获评“高质量发展综合奖”“泰兴市2023年度科技创新十佳企业”等四大荣誉,济川有限及董事长曹龙祥荣获“国家科学技术进步二等奖”。","listedPrice":7.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"济川药业,600566,济川药业股票,济川药业股票老虎,济川药业股票老虎国际,济川药业行情,济川药业股票行情,济川药业股价,济川药业股市,济川药业股票价格,济川药业股票交易,济川药业股票购买,济川药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}